Pesquisar
Genmab A/S
GMABAdicionar à lista de desejos
28.860USD
+0.220+0.77%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
17.78BValor de mercado
21.74P/L TTM
Mais detalhes de Genmab A/S Empresa
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Informações de Genmab A/S
Código da empresaGMAB
Nome da EmpresaGenmab A/S
Data de listagemOct 01, 2000
CEOVan De Winkel (Jan G.J)
Número de funcionários2682
Tipo de títulosDepository Receipt
Fim do ano fiscalOct 01
EndereçoCarl Jacobsens Vej 30
CidadeVALBY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísDenmark
Código postal2500
Telefone4570202728
Sitehttps://www.genmab.com/
Código da empresaGMAB
Data de listagemOct 01, 2000
CEOVan De Winkel (Jan G.J)
Executivos da empresa Genmab A/S
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Genmab A/S?
Os cinco principais acionistas de Genmab A/S são: Dr. Jan G.J. Van De Winkel, Ph.D.
Quantas instituições possuem ações da Genmab A/S (GMAB)?
Em 2026Q1, 564 instituições possuíam ações da Genmab A/S, com valor de mercado aproximado de 74.31M, representando 12.10% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2989185.00.
Qual é a maior fonte de receita da Genmab A/S?
Em 2026Q1, o segmento de negócios Royalties gerou a maior receita para Genmab A/S, totalizando 3.10B e representando 83.39% da receita total.